Equities

Sedana Medical AB (publ)

Sedana Medical AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)23.15
  • Today's Change0.000 / 0.00%
  • Shares traded39.02k
  • 1 Year change+27.20%
  • Beta0.4722
Data delayed at least 15 minutes, as of Sep 19 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The one analyst offering a 12 month price target expects Sedana Medical AB (publ) share price to rise to 43.00 in the next year from the last price of 23.15.
High85.7%43.00
Med85.7%43.00
Low85.7%43.00

Dividends in SEK

Dividend information is not available for Sedana Medical AB (publ).
Div growth (TTM)--
More ▼

Earnings history & estimates in SEK

On Jul 23, 2024, Sedana Medical AB (publ) reported 2nd quarter 2024 losses of -0.18 per share.
The next earnings announcement is expected on Oct 24, 2024.
Average growth rate-442.86%
Sedana Medical AB (publ) reported annual 2023 losses of -0.600 per share on Feb 15, 2024.
Average growth rate-44.69%
More ▼

Revenue history & estimates in SEK

Sedana Medical AB (publ) had 2nd quarter 2024 revenues of 41.06m. This missed the 45.00m consensus estimate of the 2 analysts following the company. This was 8.67% above the prior year's 2nd quarter results.
Average growth rate+3.90%
Sedana Medical AB (publ) had revenues for the full year 2023 of 153.87m. This was 25.23% above the prior year's results.
Average growth rate+28.14%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.